Abstract
OBJECTIVE: To determine the quality of life in patients with multiple myeloma treated with vertebroplasty. Multiple myeloma has a prevalence of 1% in all neoplastic diseases and 10% of hematological malignancies. Bone pain is the initial symptom in most cases. METHODS: A series of cases study was conducted. Patients were assessed by the Karnofsky scale to measure its functionality, the WHO analgesic scale to assess the type of analgesic and visual analog scale (VAS) and the Oswestry questionnaire for pain. RESULTS: Of 24 patients, 10 were cases (vertebroplasty) (41.7%) and 14 were controls (conservative) (58.3%), 13 (54.2%) were female and 11 (45.8%) male, with an average age of 60 years (SD = 12) and 63 kg of average weight (SD = 12), mean height of 1.59 cm (SD = 9) and mean body mass index of 24.8 (SD = 3.7). Survival was obtained from the time of diagnosis to death, and 2 (8.3%) patients died within the first 2 years and 1 (4.2%) after 3 years. CONCLUSIONS: Patients with MM who have vertebral fractures are excellent candidates to undergo vertebroplasty, because this represents a greater benefit in their quality of life, which has a direct impact on their level of functionality, giving them greater self-sufficiency and reducing their pain because of the benefits of the thermogenic effect of vertebroplasty.
Highlights
Multiple myeloma (MM) represents 1% of all neoplasias and 10% of malignant hemopathies, with an annual incidence in our country of [3,4] new cases per 100,000 people
Ignacio García Téllez hospital in Guadalajara, Jalisco, of the patients who had the hematological disorder multiple myeloma (MM), treated conservatively and surgically with vertebroplasty, were reviewed. Patients of both sexes and any age were included, diagnosed with MM according to the criteria of the International Myeloma Working Group and who underwent vertebroplasty for the treatment of spinal fractures, regardless of the amount of time elapsed since the procedure, or who were treated conservatively, as well as patients in any stage of MM and with any comorbidity
Patients with any other pathology, who did not meet the diagnostic criteria of the International Myeloma Working Group, or those who were lost during follow-up and could not be located for evaluation, were not included
Summary
Multiple myeloma (MM) represents 1% of all neoplasias and 10% of malignant hemopathies, with an annual incidence in our country of [3,4] new cases per 100,000 people. The average age of presentation is around 65 years, and it is rare in individuals younger than 30 years of age (0.3% of all cases). 12% are aged under 50 years of age, and only 2% are aged under 40 years.. 1. Orthopedics and Traumatology Service of the Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social [Mexican Institute of Social Security], Guadalajara, Jalisco, Mexico. Differential diagnosis with Monoclonal Gammopathy of Undetermined Significance (MGUS), quiescent myeloma (QM), primary amyloidosis (AL), and metastatic carcinoma is suggested.[2]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call